PARTNERING WITH SERVIER

SERVIER

moved by you

SERVIER
moved by you

AMBITIOUS STRATEGY, STRONG FINANCIAL RESOURCES
Governed by Foundation:
long term & independent

TRACK RECORD OF SUCCESS
In building our oncology pipeline but now also focused on partnering in rare neurological disorders

A RELIABLE, LONG-TERM PARTNER
Interested in assets from late research through to late clinical

PATIENTS AT THE HEART OF EVERYTHING WE DO
Innovating for the benefit of patients

Your strategic partner

We are a private, midsize pharmaceutical company, owned by a foundation.

Our independence enables a long-term vision and gives us the freedom to make our own strategic decisions.

We are committed to therapeutic progress to service patient needs and driven by a bold ambition to double our revenue by 2030 by reaching €10 billion in sales.

We are present in all the key innovation ecosystems in the world with capabilities ranging from R&D, commercial and manufacturing.

This includes 4 R&D centers, 15 clinical development centers, 14 manufacturing sites and commercial capabilities across the globe.

We are convinced that combining internal and external innovation will enable us to respond to major therapeutic challenges.

22k
Employees

4
Research centers

3
Hubs
(North and South America, Europe, Asia-Pacific)

15
Development centers

14
Production sites

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING

Oncology

Therapeutic modalities & technologies

AI & digital technologies applied to R&D

Neurology

Drug discoveries & development technologies

Digital, Data, AI & Beyond-the-Pill

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING

Expanding our ONCOLOGY pipeline to meet patient needs

We are expanding Servier's pipeline in selected oncology disease areas at all development stages, from research to late clinical.

PARTNERING INTERESTS

Key focus disease areas

PRIMARY

- **LEUKEMIA** AML, ALL, MDS, MPNs
- **BRAIN**
- **GI** PDAC, CRC, BTC, Gastric, Esophageal, Others[1]

SECONDARY

- **MASS TREATERS** LUNG
- **RARE CANCERS**
- **LYMPHOMA** NHL, HL
- **LONG TAIL** GIST/ Sarcoma

MODALITIES

- **ANTIBODIES** (mAb, ADC, bi-tri specific, TCE)
- **SMALL MOLECULES**

Deal types

Global rights as a priority or regional (EU or US followed by China or Japan)

Late-stage clinical focus

Hematologic tumors (ALL, AML, MDS)

Solid tumors (GI & CNS as a priority)

Discovery & early-stage clinical focus

Cancer cell targeting:

Synthetic lethality

Apoptosis

Precision oncology

- Biomarker-defined populations

Immuno-oncology:

Tumor immune micro-environment

- T-cell targeting

1. Others include but not limited to small intestine, anal, appendiceal, Gyn, GU, H&N, thyroid, thymoma.

PARTNERING CONTACTS

Global BD

Anne Dagallier
Global Head of Licensing Oncology
anne.dagallier@servier.com

Valérie Agrapart, PharmD
Director, Business Development Oncology
valerie.agrapart@servier.com

R&D Search& Evaluation

Irene Blat, PhD
Senior Director, Search & Evaluation, Oncology
irene.blat@servier.com

Alix Scholer-Dahirel, PharmD
Director, Business Development Oncology
alix.scholer-dahirel@servier.com

Julie Legrand
Director, Business Development Oncology
julie.legrand@servier.com

Global BD Coordination

Trinh Lam
GBD Coordination Officer, Oncology
trinh.lam@servier.com

Local BD Asia-Pacific

Cynthia Wang, MBA, MSc
Director, Business Development
cynthia.wang@servier.com

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING

Building an innovative pipeline in NEUROLOGY

Our ambition is to build a new franchise in Rare Neurological Disorders by 2030. Similar to oncology, we will concentrate on hard-to-treat diseases with high medical needs.

PARTNERING INTERESTS

Key focus disease areas

PRIMARY

- **RARE MOVEMENT DISORDERS**[1]
  FA, SCA, MSA, PSP, HD
- **NEUROMUSCULAR DISORDERS**[2]
  ALS, SMA, DMD, FSHD, DM, MG
- **REFRACTORY EPILEPSIES**[3]
  DS, LGS, JS, WS, OTHER DEES

SECONDARY

- **LEUKODYSTROPHIES**
- **GENETICALLY DRIVEN ASD**[4]
  PMD, RETT, AG
- **PERIPHERAL NEUROPATHIES**[5]
  CMT, CIDP

MODALITIES

- **ANTIBODIES**
- **OLIGONUCLEOTIDES**
- **SMALL MOLECULES**

1. FA: Friedreich Ataxia; SCA: Spinocerebellar Ataxia; MSA: Multiple system Atrophy; PSP: Progressive Supranuclear Palsy; HD: Huntington Disease
2. ALS: Amyotrophic Lateral Sclerosis; SMA: Spinal Muscular Atrophy; DMD: Duchene Muscular Atrophy; FSHD: Fascioscapulohumeral Dystrophy; DM: Myotonic Dystrophy; MG: Myasthenia Gravis
3. DS: Dravet Syndrome; LGS: Lennox-Gastaut Syndrome; JS: Jeavons Syndrome; WS: West Syndrome; DEE: Developmental and Epileptic Encephalopathies
4. ASD: Autism Spectrum Disorders; PMD: Phelan McDermid Syndrome; AG: Angelman Syndrome
5. CMT: Charcot-Marie-Tooth; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy

PARTNERING CONTACTS

Global BD

David Theron
Project Director Neurology
david.theron@servier.com

R&D Search & Evaluation

Camille Nicoleau, PhD
Director, Search & Evaluation, Neurology
camille.nicoleau@servier.com

Local BD

Asia-Pacific

Cynthia Wang, MBA, MSc
Director, Business Development
cynthia.wang@servier.com

Global BD Coordination

Lara Maria Matar
GBD Coordination Officer, Neurology
laramaria.matar@servier.com

SERVIER moved by you

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING

Therapeutic modalities & technologies

PARTNERING INTERESTS

Small Molecules

- Kinase, PPi, Receptor modulators; Molecular Glues, Bifunctional molecules, Small molecule targeting RNA for targeted protein degradation/upregulation
- Targeted delivery: prodrugs/polymer drug conjugates/targeted Lipid Nano Particles, Exosomes, Extracellular Vesicles
- Compound Library

Antibodies

- Novel Formats: Ab Fragments, Single Domain Antibodies, Bi-/ Multi-specifics, optimized Fc domains
- Novel technology platform for Antibody Hard-to-Drug targets
- Synthetic antibody libraries
- ADCs linkage Chemistry/ Conditionally active antibody format

Oligonucleotides

- Novel Monomers, Antisense Oligonucleotide (ASO) design technologies, ASO-conjugates and drug delivery systems, targeted saRNA, selective cell ligand targeting for neuronal cell delivery
- Oligo-Manufacturing

PARTNERING CONTACTS

R&D Search & Evaluation

Georges Da Violante
Director, Search & Evaluation, Enabling Technologies
georges.da-violante@servier.com

Global BD Coordination

Delphine Duong
GBD Coordination Officer, Research Transactions
delphine.duong@servier.com

Drug discovery & development technologies

PARTNERING INTERESTS

Phenotypic cell platforms & 3D models

- iPSCs, patient derived models
- Co-culture models
- Organoids, tumoroids (PDAC, CRC, other solid tumors)
- Organ on a chip (liver, brain, kidney)

Protein sciences imaging

- High throughput functional & stability antibody screening
- Antigen specific immuno-oncology assays
- Microfluidic or micro array technology B-cell workflow
- Multi-protein production
- High throughput mass spectrometry based proteomic analysis approach
- Mass spectrometry target

Imaging

- High content imaging (tissues/cells) and analysis
- Multimodal platforms -multiplexing, spatial multiomics strategy, spatial phenotypic quantification
- In vivo visualization of antisense oligonucleotides (ASO) biodistribution
- ASO tolerability assays

Sample optimization

- Universal sample preparation
- Laser Capture Microdissection
- Single cell analysis ATAC (Assay for Transposase Accessible Chromatin)
- High throughput Mass Spectrometry based proteomic analysis approach

Liquid Biopsies

- Circulating tumor DNA (ctDNA) and methylation assay development
- Circulating tumor cells (CTC)
- Exosomes or extracelllar vesicle extraction from blood for biomarker identification
- Technology to improve sensitivity
- Computational methods for Next-Generation Sequencing

Flow chemistry

- Multistep synthesis
- Photochemistry, electrochemistry
- Automation of downstream process (quenching, phase separation, distillation)
- Continuous crystallisation/drying/milling
- In line analysis
- Continuous manufacturing in pharma

DISCOVER OUR AREAS OF FOCUS FOR PARTNERING

AI & digital technologies applied to R&D

PARTNERING INTERESTS

Focusing on a patient centered use of AI and digital technologies to:

- Enrich our pipeline by either developing first in class new drugs or by repurposing existing drugs
- Improve treatment effectiveness, reduce adverse effects and enhance patient outcomes
- Accelerate our drug discovery & development processes

Main thematic of our data analytics strategy:

Early research

- Target identification and validation, hit screening and validation, drug design, patient stratification

Late research

- Treatment understanding, DMTA cycle optimization, disease understanding, biomarker identification

Early development

- Disease modelling, optimization of clinical trial design, biomarker validation
- Drug product development & characterization

Late development

- Strategy for patient finding and site selection, optimization of medical authoring, patient-centric clinical trial execution, pharmacovigilance processes optimization

Therapeutic modalities:

- Small molecules, antisense oligonucleotides (ASO), antibodies (mAbs, bispecifics, ADCs)

PARTNERING CONTACTS

R&D Search & Evaluation

Franck Augé, PhD
Director, Search & Evaluation, AI & Digital Technologies
franck.auge@servier.com

Global BD Coordination

Delphine Duong
GBD Coordination Officer, Research Transactions
delphine.duong@servier.com

Digital, Data, AI opportunities & Beyond-the-Pill solutions

PARTNERING INTERESTS

Preferred digital & AI use cases

Initiatives focusing pharma operational efficiency & decision-making

- AI medical, health equity and patient insights management
- Sales forecasts, supply chain, manufacturing & employee optimization

Examples of solutions supporting health care professional (HCPs) activities

- Clinical decision support tools and clinical trials platform optimization
- Remote patient monitoring & dashboards

Examples of beyond-the-pill solutions supporting patients & caregivers

- Solutions supporting adherence (esp. chronic disease) & quality of life
- Patients journey insights and personalization (esp. oncology)
- Solutions offering education and gamification possibilities

PARTNERING CONTACTS

WeHealth Digital Factory

Véronique Frechin
Head of Department, Scouting, Partnerships & Strategy WeHealth Digital Factory
veronique.frechin@servier.com

Grégoire Guillet
Chief Business & Value Officer
gregoire.guillet@servier.com

Fiona Clemente
Scouting Manager
fiona.clemente@servier.com

Gaëlle Nou
Scouting Officer
gaelle.nou@servier.com

Preferred modalities

Geographic scope

- Worldwide (or regional)

Deal types

- Co-development, licenses, strategic partnerships & beyond

Preferred maturity stage & technical aspects

- Ready to use solutions
- Previous pharma partnerships
- Medical device (depending on use case)
- Clinical benefits targeted

SERVIER

moved by you

Partner with us.